Skip to search formSkip to main contentSkip to account menu

ramosetron

Known as: 5-((1-methyl-3-indolyl)carbonyl)-4,5,6,7-tetrahydro-1H-benzimidazol 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The… 
Highly Cited
2013
Highly Cited
2013
Chemotherapeutic agents, including 5‐fluorouracil (5‐FU), frequently cause intestinal mucositis resulting in severe diarrhoea and… 
Review
2011
Review
2011
  • R. Spiller
  • Current opinion in pharmacology
  • 2011
  • Corpus ID: 28268571
Highly Cited
2009
Highly Cited
2009
BACKGROUND Ramosetron is a new selective 5-hydroxytryptamine type 3 (5-HT(3)) receptor antagonist that reportedly has more potent… 
Highly Cited
2009
Highly Cited
2009
BackgroundPatients undergoing general anesthesia for laparoscopic cholecystectomy are at high risk for postoperative nausea and… 
Highly Cited
2008
Highly Cited
2008
Study Design. A prospective, randomized, double-blind clinical trial. Objective. To compare the effect of ramosetron with that of… 
Review
2002
Review
2002
Ramosetron is a selective serotonin 5-HT3 receptor antagonist with an affinity higher than that of the previously available drugs… 
Highly Cited
2000
Highly Cited
2000
UNLABELLED In a prospective, randomized, double-blinded, placebo-controlled trial, we evaluated the efficacy of ramosetron at… 
Highly Cited
1999
Highly Cited
1999
UNLABELLED In a prospective, randomized, double-blinded study, we evaluated the efficacy of granisetron and ramosetron for…